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ess: wlenney@lycos.comSummary Families with asthmatic children were recruited to take part in a multi-
centre collaborative study into the genetics of asthma. Detailed phenotypic
information was collected on all family members including: lung function,
anthropomorphic measurements, response to methacholine challenge, skin prick
testing, serum IgE measurements and a detailed nurse-administered questionnaire.
Families were eligible for entry into the study if they had two children with a doctor-
diagnosis of asthma. Bennett/Twin nebulisers were supplied to each centre from a
single source and these were calibrated to determine gravimetric nebuliser output
prior to use. Asthmatic probands from each centre had similar degrees of asthma
severity and atopy. There was no significant difference in the sex ratios or ages of the
probands or numbers of parents with a history of smoking in the families recruited at
each centre. However, there was a significant difference in the number of children
with airway hyperresponsiveness, with 90% of the North Staffordshire group but only
60% of the Sheffield group having a PC20 of o8mg/ml for methacholine. This
difference highlights the difficulty of using families from different centres in genetic
and epidemiological studies.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Asthma is a heterogenous condition, the clinical
label covering a wide-spectrum of disease severity
and clinical expression.1 This variability has ham-
pered many of the genetic and epidemiological
studies conducted to date. One strategy that may
be useful in countering this is to collect high quality
objective phenotypic information on participants.
However, interpreting this information and com-
paring results between centres raises its own
difficulties.
Although a universally agreed definition for
asthma remains elusive, there is broad agreement
that airway hyperresponsiveness (AHR) is one of the
core elements of the asthma phenotype.2 There are
several methodologies available to assess this,
including direct3 and indirect airway challenges.4,5
Arguments persist about which of these tests is
most representative of AHR in vivo. However,
methacholine challenge by the tidal-breathing
method remains an accepted and standard meth-
odology for assessing AHR in both adults and
children.6
In order to unpick the interplay of environmental
and genetic factors that undoubtedly occur in
asthma, large family studies may prove more
successful than case-control studies in identifying
genes which play an important role in the
pathogenesis of asthma.7 Transmission disequili-
brium testing (TDT) detects allelic association
with disease if heterozygous parents exhibit de-
parture from expected 50:50 Mendelian transmis-
sion, by preferentially transmitting a specific
allele to the offspring with the disease.8 As this
relies only on allele transmission with families it
does not suffer from the problems of population
stratification. Unfortunately, for genes of modest
effect (relative risk 1.5) TDT analysis requires very
large numbers of families (42000).7 Moreover,
recruitment to such studies is difficult and time-
consuming9 and even the largest centres are
unlikely to be able to recruit enough families to
have sufficient power to reliably detect important
genetic effects.
Between 1999 and 2001 North Staffordshire and
Sheffield were two of the centres which took part in
an international collaborative study into the genet-
ics of asthma. Both centres recruited families via
an asthmatic proband, additionally recruiting at
least one asthmatic sibling and both parents
whether asthmatic or not. Detailed phenotypic
information was collected on all participants. Here
we report in detail on the observed differences in
baseline demographics of the two populations of
asthmatic families.Methods
A total of 162 Caucasian families with at least 2
asthmatic children (aged 7–35 years) were re-
cruited via an asthmatic proband from the two
centres (North Staffordshire and Sheffield) be-
tween January 1999 and December 2001 as part
of a larger multi-centre collaborative study. Inclu-
sion criteria for the probands included documented
episodes of wheezing in the previous 12 months,
physician diagnosis of asthma, affected sibling with
documented symptoms, treatment for asthma for
at least 2 years and agreement to participate of the
natural mother and father. Identical twins were not
eligible to participate and subjects with cardiac,
other respiratory or inflammatory diseases were
excluded. The study was approved by the local
research ethics committee at each centre and
written informed consent was obtained from all
families.
Participants completed a standardised ob-
server-administered ISAAC questionnaire,10 under-
went baseline spirometry11 and methacholine
challenge testing (tidal breathing method).6 Iden-
tical Bennett/Twin nebulisers were supplied to
each centre from a single manufacturer. The
flow rate required for each nebuliser was estab-
lished using gravimetric calibration so that flow
was set to produce an output of 0.13ml/min.
Nebulisers in each centre were driven by air
cylinders providing identical driving pressures
(50 p.s.i.).
Asthma severity was attributed retrospectively
on questionnaire data on the basis of symptoms and
treatment using a simple algorithm (see Appendix).
One person in Stoke (WDC) and one in Sheffield (AP)
carefully re-evaluated all the severity scores by
individually scrutinising the original documentation
completed at study entry relating to symptoms,
treatment and lung function for all family mem-
bers. Inter-centre severity scoring repeatability
was checked by blinded reassignment of 10% of
the original sample. Individuals were defined as
having: (1) no asthma; (2) intermittent asthma; (3)
mild asthma; (4) moderate asthma or (5) severe
asthma.
Skin prick testing (SPT) and measurement of
total serum IgE (Immulite assay, Euro/DPC Ltd.,
Gwynedd, Wales, UK) were performed on all
subjects. Atopy was defined as a positive response
to SPT (X1 wheal X3mm greater than saline
response to a panel of 7 aeroallergens) or a total
serum IgE X100 IU/ml. Lung function results in
children were expressed as percentage of predicted
for height.12 Spirometry in both centres was
undertaken in a dedicated lung function laboratory
ARTICLE IN PRESS
Table 1 Demographic comparisons of probands recruited in North Staffordshire and Sheffield.
North Staffordshire n=72 Sheffield n=90 P-value difference
Median age 7 SD 12.06 12.63 0.694
Gender (% male) 66.7 62.5 0.584
Atopic (%)* 83.3 87.8 0.421
On inhaled steroids (ICS) (%) 75.0 77.8 0.662
ICS median dose (BDP)y 400 400
Median basal FEV1 7 SD (%)
z 101.5 7 14.9 97.4 7 16.3 0.071
Median basal FVC 7 SD (%)z 102.1 7 12.4 98.9 7 16.3 0.062
Median FEV1:FVC 7 SD (%)
z 98.9 7 10.6 99.2 7 9.3 0.872
Parental history of smoking 47.6% 40.6% 0.283
PC20 o8mg/ml 93.0% 61.2% o0.001
PC20 o4mg/ml 83.1% 51.8% o0.001
Median DRS 7 SD 21.2 4.1 o0.001
Not asthmatic (%) 4.2 4.4
Intermittent asthma (%) 12.5 22.2
Mild asthma (%) 34.7 37.8 0.688
Moderate asthma (%) 27.8 22.2
Severe asthma (%) 20.8 13.3 0.288
Hospital recruitment 44.3% 3.5%
Community recruitment 55.7% 96.5% o0.001
zLung function expressed as a percentage of predicted.12
*Atopy defined as either serum IgE 487 kU/l or Skin Prick Test positive.
yExpressed as dose of beclomethasone equivalent in micrograms.
Regional Variation of AHR 405in accordance with American Thoracic Society
standards.13
The response to methacholine was expressed
as a PC20 and as a dose-response slope (DRS).
All probands underwent methacholine challenge
except where it was contraindicated because of
an forced expiratory volume in IS (FEV1) o70%.11
Five probands from Stoke (6.9%) and 7 probands
from Sheffield (7.7%) fell into this category and
therefore underwent bronchodilator challenge
only.Statistical analysis
Differences between the probands in the two
centres were assessed using the Mann–Whitney U-
test for continuous variables and Chi-squared
testing for categorical outcomes. All statistical
analyses were performed using the Stata (version
8.0: Stata corportation, College Station, Texas) and
StatXact statistical packages (version 4.0: Cytel
corporation, Cambridge, Mass). To test the hypoth-
esis that AHR was influenced by centre after
correction for known confounding factors we
performed linear and logistic regressions on the
logarithms of DRS and on PC20 o8mg/ml metha-
choline, respectively.Results
During the study period 90 families were recruited
from Sheffield and 72 from North Staffordshire. For
most of the phenotypic information collected, the
probands at each centre were remarkably similar.
However, there was a marked difference in the AHR
seen between the two groups. These data are
presented in Table 1. Mean basal lung function as
measured by FEV1 and forced vital capacity (FVC)
were marginally higher in the North Staffordshire
children but this difference did not reach statistical
significance (P40:05). The decreased AHR in the
Sheffield probands was not related to asthma
severity or differences in treatment with inhaled
corticosteroids. Asthma severity scores were very
similar between the centres and the proportion of
children with mild asthma (34.7% versus 37.8%
P ¼ 0:688) and severe asthma (20.8% versus 13.3%
P ¼ 0:288) were not significantly different between
the two centres. Inter-rater agreement in severity
scoring was very high (r ¼ 0:95). The proportion of
children treated with inhaled corticosteroids was
almost identical in each centre (75% versus 77.8%
P ¼ 0:662).
The proportion of children recruited from hospi-
tal and community sources was different between
the two centres (Table 2). However, regression
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Table 2 Recruitment source of families by center.
Source North Staffordshire n=70 Sheffield n=85 P-value difference
Email/internet 0 (0%) 2 (2%) 0.502
GP referral 0 (0%) 28 (33%) o0.001
Hospital clinic/Ward 31 (44%) 3 (4%) o0.001
School survey/doctor 26 (37%) 36 (42%) 0.621
Leaflet 6 (9%) 14 (16%) 0.158
Other 7 (10%) 2 (2%) 0.080
Table 3 Regression analyses of potential confounders for AHR in probands.
Potential predictor of AHR Linear regression vs ln DRS Logistic regression vs PC20 o8mg/ml
Centre Po0.001 Po0.001
FEV1 as % predicted P=0.963 P=0.375
FVC as % predicted P=0.710 P=0.228
FEV1:FVC as % predicted P=0.194 P=0.094
Atopic status P=0.008 P=0.354
Parental smoking status P=0.248 P=0.142
Severity score P=0.008 P=0.226
Oral steroids in last 12 months P=0.936 P=0.322
Recruitment source P=0.652 P=0.735
W.D. Carroll et al.406analysis did not demonstrate a significant associa-
tion with recruitment source and measures of AHR
(DRS or PC20) (Table 3).Discussion
Large differences in airway hyperresponsiveness
(AHR) have been shown between patients with
asthma in North Staffordshire and in Sheffield.
These patients had similar asthma severity scores
and treatment with inhaled corticosteroids. More-
over, they were all Caucasian and were recruited as
part of the same large international multicentre
genetics of asthma study. These apparent differ-
ences are unexpected and difficult to explain.
Prior to data collection, great care was taken to
ensure that data collected from our two centres
would be comparable. This included provision of
much of the equipment for patient assessment from
a central source, identical questionnaires and
laboratory protocols.6,10 Because of the strict
inclusion and exclusion criteria for entry into the
study recruitment was difficult at each center.9 A
lower proportion of families recruited in Sheffield
was recruited from hospital sources (Po0.001).
However, recruitment source did not significantly
influence AHR, nor was it a predictor of asthma
severity in either centre.Differences in AHR between different centres
have been reported previously.14 However, re-
ported differences within the same country are
usually relatively small.15 In the European Commu-
nity Respiratory Health Survey (ECHRS) one poten-
tial confounder which has been identified is the
driving pressure of the nebuliser.16 As identical
driving pressures (50 p.s.i) were used in each centre
this does not account for our results.
Given the geographical proximity of our two
centres we were surprised to see such a large
difference in AHR. Even in retrospect this cannot
be explained by differences in laboratory proce-
dures, asthma severity or recruitment procedures.
Although AHR remains one of the important pheno-
typic measures of asthma, this large variation
between centres may mask important genetic
effects and highlights the difficulty of inter-centre
collaboration in genetic and epidemiological studies.Acknowledgements
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Regional Variation of AHR 407Appendix. Asthma severity scoringWheeze in last  
12 months? 
NO 
1. Not asthma
ANY YES 
Day symptoms >1/week
Night symptoms>1/month 
Treatment with inhaled steroid
2. Intermittent asthma
ALL NO 
YES 
Day symptoms >1/day
Night symptoms >1/week
Treatment with LABA/LRTA
3. Mild-persistent asthma
ALL NO 
ANY YES 
Mean basal FEV1 < 60%
Continuous symptoms
Frequent exacerbations 
Oral steroids 
ANY YES 
5. Severe-persistent asthma
4. Moderate-persistent 
asthma
ALL NO 
≥ 2mg BDP equivalentReferences
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